Other Briefings
India Notifies Dholera SEZ in Boost for Semiconductor Ecosystem
India notifies the Dholera SEZ in April 2026, establishing a premier global hub for semiconductor and electronics manufacturing. The 66-hectare zone features on-site customs (ICD) and strategic connectivity in the Delhi-Mumbai Industrial Corridor.
India’s Food Processing Industry in 2026: Growth Trends, PLI Impact, and Export Performance
India’s food processing industry in 2026 is expanding steadily, driven by PLI incentives, rising foreign direct investments, export growth, and strong domestic demand, positioning it as a key engine of value addition and employment.
US Pharma Tariff 2026: Decoding the 100% Patented Drug Levy and the Generic Exemption
The US administration under President Donald J. Trump has implemented a 100% tariff on patented pharma products to curb import dependence. While Indian generics are exempt for now, a one-year review and API onshoring rules signal long-term shifts.
City Spotlight: Sanand, Gujarat—Semiconductor Momentum Meets Industrial Depth
Sanand, Gujarat, is bridging the gap in India’s semiconductor value chain. Discover how cluster-based development and the India Semiconductor Mission (ISM) are driving multi-million-dollar investments in automotive and AI chip manufacturing.
Noida and Greater Noida: Delhi-NCR’s Investment Corridor—IT, Manufacturing, and Jewar Airport
From IT hubs to industrial corridors, learn why the Noida, Greater Noida, and Jewar corridor is the new anchor of Delhi’s NCR. Get insights on land, policy, and 2026 project pipelines.
Beyond Oil: How Gulf Disruptions Are Rewiring Global Supply Chains
The 2026 West Asia conflict has triggered a systemic, multi-sector shock, with disruptions to urea and helium exports from the Gulf constraining global agriculture and semiconductor manufacturing supply chains.
India’s Race to Manufacture Affordable Obesity Drugs Amid Ozempic’s Market Entry
India’s obesity-drug market is transforming as semaglutide goes off patent, driving Ozempic’s generic manufacturing, price shifts, and new opportunities in GLP-1 therapies.
New Drug Manufacturing Rules 2026: India’s 3-Tier Change Classification & DCGI Licensing Overhaul
Navigate the 2026 drug manufacturing reforms: a guide to India’s mandatory pharma change reporting, 3-tier risk classifications, and standardized Drugs Controller General of India (DCGI) licensing norms.
